OncoTherics

OncoTherics is a UK-based biotechnology company specializing in the development of hypoxia-activated prodrugs (HAPs) for the treatment of solid tumors. A spin-out from the University of Bradford's Institute of Cancer Therapeutics, the company leverages proprietary technology to design small molecules that are selectively activated in the low-oxygen environments characteristic of many cancers. This targeted approach is intended to overcome the resistance of hypoxic tumor cells to conventional radiotherapy and chemotherapy while reducing systemic toxicity. The company's lead program, OCT-1002, is a prodrug designed to be converted into a potent DNA-binding agent by specific enzymes within the tumor microenvironment. By focusing on the unique physiology of the tumor, OncoTherics aims to provide more effective therapeutic options for difficult-to-treat cancers such as prostate and breast cancer.